Eprosartan mesylate
Suppliers
Names
[ CAS No. ]:
144143-96-4
[ Name ]:
Eprosartan mesylate
[Synonym ]:
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid,methanesulfonic acid
4-({2-Butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzolcarbonsäure-methansulfonsäure(1:1)
acide 4-({2-butyl-5-[(1E)-2-carboxy-3-thiophén-2-ylprop-1-én-1-yl]-1H-imidazol-1-yl}méthyl)benzoïque - acide méthanesulfonique (1:1)
MFCD08141807
2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, methanesulfonate (1:1)
Eprosartan mesylate
4-({2-butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate
2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αZ)-, methanesulfonate (1:1)
Eprosartan Monomethanesulfonate SKF-108566J Teveten
4-({2-Butyl-5-[(1Z)-2-carboxy-3-(2-thienyl)-1-propen-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1)
4-({2-Butyl-5-[(1E)-2-carboxy-3-(2-thienyl)-1-propen-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1)
4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1)
Eprosartan (mesylate)
Chemical & Physical Properties
[ Density]:
1.26 g/cm3
[ Boiling Point ]:
660.6ºC
[ Melting Point ]:
248 °C
[ Molecular Formula ]:
C24H28N2O7S2
[ Molecular Weight ]:
520.618
[ Flash Point ]:
353.3ºC
[ Exact Mass ]:
520.133789
[ PSA ]:
183.41000
[ LogP ]:
5.32920
[ Vapour Pressure ]:
2.37E-18mmHg at 25°C
[ Storage condition ]:
room temp
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319
[ Precautionary Statements ]:
P305 + P351 + P338
[ Hazard Codes ]:
Xi
[ Risk Phrases ]:
36/37/38
[ Safety Phrases ]:
26
[ RIDADR ]:
NONH for all modes of transport
[ HS Code ]:
2934999090
Customs
[ HS Code ]: 2934999090
[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
BMC Immunol. 10 , 52, (2009)
Growing knowledge about cellular interactions in the immune system, including the central role of cytokine networks, has lead to new treatments using monoclonal antibodies that block specific componen...